[{"id":"6a10d540-3227-4566-8606-34570d8b161e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04580485","created_at":"2021-02-24T11:03:20.215Z","updated_at":"2025-02-25T14:07:56.143Z","phase":"Phase 1","brief_title":"INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors","source_id_and_acronym":"NCT04580485","lead_sponsor":"Incyte Corporation","biomarkers":" CD8","pipe":"","alterations":" ","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynyz (retifanlimab-dlwr) • INCB106385"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 02/03/2021","start_date":" 02/03/2021","primary_txt":" Primary completion: 01/22/2024","primary_completion_date":" 01/22/2024","study_txt":" Completion: 01/22/2024","study_completion_date":" 01/22/2024","last_update_posted":"2025-02-18"},{"id":"3aa72670-9b0b-4205-9807-1cc48204caf9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05335941","created_at":"2022-04-20T16:53:38.622Z","updated_at":"2025-02-25T15:35:35.713Z","phase":"Phase 2","brief_title":"A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma","source_id_and_acronym":"NCT05335941","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MTAP • IL17A","pipe":"","alterations":" ","tags":["MTAP • IL17A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pemetrexed • Yutuo (zimberelimab) • etrumadenant (AB928)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/13/2023","start_date":" 06/13/2023","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2025-02-10"},{"id":"15f2feeb-91bd-4d1e-8210-eb0dea4872da","acronym":"ARC-7","url":"https://clinicaltrials.gov/study/NCT04262856","created_at":"2021-01-18T20:42:57.527Z","updated_at":"2024-07-02T16:35:00.997Z","phase":"Phase 2","brief_title":"Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04262856 - ARC-7","lead_sponsor":"Arcus Biosciences, Inc.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression • PD-L1 overexpression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yutuo (zimberelimab) • domvanalimab (AB154) • etrumadenant (AB928) • mitazalimab (ADC-1013)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 151","initiation":"Initiation: 05/28/2020","start_date":" 05/28/2020","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-05-24"},{"id":"409dc71f-d788-44b0-9225-6f9acd37a635","acronym":"ARC-4","url":"https://clinicaltrials.gov/study/NCT03846310","created_at":"2021-01-18T18:59:18.192Z","updated_at":"2024-07-02T16:35:01.028Z","phase":"Phase 1","brief_title":"A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer","source_id_and_acronym":"NCT03846310 - ARC-4","lead_sponsor":"Arcus Biosciences, Inc.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • pemetrexed • Yutuo (zimberelimab) • etrumadenant (AB928)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 77","initiation":"Initiation: 04/01/2019","start_date":" 04/01/2019","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2024-05-24"},{"id":"e5aa0f89-24de-40bf-8a67-186c3db1a88b","acronym":"ARC-2","url":"https://clinicaltrials.gov/study/NCT03719326","created_at":"2021-01-18T18:13:45.819Z","updated_at":"2024-07-02T16:35:01.152Z","phase":"Phase 1","brief_title":"A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies","source_id_and_acronym":"NCT03719326 - ARC-2","lead_sponsor":"Arcus Biosciences, Inc.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • ER negative • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • pegylated liposomal doxorubicin • eganelisib (IPI-549) • etrumadenant (AB928) • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 35","initiation":"Initiation: 10/15/2018","start_date":" 10/15/2018","primary_txt":" Primary completion: 07/01/2021","primary_completion_date":" 07/01/2021","study_txt":" Completion: 07/02/2021","study_completion_date":" 07/02/2021","last_update_posted":"2024-05-24"},{"id":"1a88a82a-3303-489f-8916-22ffac696e62","acronym":"CURATE","url":"https://clinicaltrials.gov/study/NCT05272709","created_at":"2022-03-09T12:52:43.513Z","updated_at":"2024-07-02T16:35:04.084Z","phase":"Phase 1/2","brief_title":"TT-702 in Patients With Advanced Solid Tumours.","source_id_and_acronym":"NCT05272709 - CURATE","lead_sponsor":"Cancer Research UK","biomarkers":" HER-2 • ER • PGR • MSI • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" HER-2 positive • HR positive • MSI-H/dMMR • HER-2 negative • ER negative","tags":["HER-2 • ER • PGR • MSI • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • MSI-H/dMMR • HER-2 negative • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nubeqa (darolutamide) • TT-702"],"overall_status":"Recruiting","enrollment":" Enrollment 188","initiation":"Initiation: 01/19/2022","start_date":" 01/19/2022","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-05-13"},{"id":"f5b1a6c8-e4d4-430b-b708-74c9cb48dc4a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04791839","created_at":"2021-03-10T12:55:03.832Z","updated_at":"2024-07-02T16:35:10.680Z","phase":"Phase 2","brief_title":"Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04791839","lead_sponsor":"Washington University School of Medicine","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yutuo (zimberelimab) • domvanalimab (AB154) • etrumadenant (AB928)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/04/2021","start_date":" 08/04/2021","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 04/30/2029","study_completion_date":" 04/30/2029","last_update_posted":"2024-04-09"},{"id":"4a225605-ea40-4786-bbe9-47b89ed77c1f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05234307","created_at":"2022-02-10T13:52:54.502Z","updated_at":"2024-07-02T16:35:14.388Z","phase":"Phase 1","brief_title":"PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05234307","lead_sponsor":"Dwight Owen","biomarkers":" PD-L1 • ALK • STK11","pipe":"","alterations":" ","tags":["PD-L1 • ALK • STK11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • PBF-1129"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/21/2022","start_date":" 11/21/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-03-15"},{"id":"e68d2a21-c443-4058-9176-91b7dbc528d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03274479","created_at":"2021-01-18T16:10:19.023Z","updated_at":"2024-07-02T16:35:20.103Z","phase":"Phase 1","brief_title":"PBF-1129 in Patients With NSCLC","source_id_and_acronym":"NCT03274479","lead_sponsor":"Palobiofarma SL","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" ALK mutation • ROS1 mutation","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK mutation • ROS1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PBF-1129"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 10/01/2018","start_date":" 10/01/2018","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2024-02-09"},{"id":"0850e024-8b63-48dd-9e35-e28737bab106","acronym":"","url":"https://clinicaltrials.gov/study/NCT04976660","created_at":"2021-07-26T17:53:24.225Z","updated_at":"2024-07-02T16:36:11.176Z","phase":"Phase 1/2","brief_title":"TT-4 as a Single Agent in Subjects With Advanced Selected Solid Tumors","source_id_and_acronym":"NCT04976660","lead_sponsor":"Tarus Therapeutics, Inc.","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PORT-7"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 69","initiation":"Initiation: 12/15/2022","start_date":" 12/15/2022","primary_txt":" Primary completion: 06/01/2023","primary_completion_date":" 06/01/2023","study_txt":" Completion: 09/30/2023","study_completion_date":" 09/30/2023","last_update_posted":"2022-05-02"}]